eFFECTOR Therapeutics Statistics
Share Statistics
eFFECTOR Therapeutics has 4.70M shares outstanding. The number of shares has increased by -92.72% in one year.
Shares Outstanding | 4.70M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 4.23M |
Failed to Deliver (FTD) Shares | 18 |
FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 91.62K, so 1.95% of the outstanding shares have been sold short.
Short Interest | 91.62K |
Short % of Shares Out | 1.95% |
Short % of Float | 2.17% |
Short Ratio (days to cover) | 0.97 |
Valuation Ratios
The PE ratio is -0.71 and the forward PE ratio is null.
PE Ratio | -0.71 |
Forward PE | null |
PS Ratio | 0 |
Forward PS | 0 |
PB Ratio | -4.41 |
P/FCF Ratio | -0.86 |
PEG Ratio | n/a |
Enterprise Valuation
eFFECTOR Therapeutics Inc. has an Enterprise Value (EV) of -.
EV / Earnings | null |
EV / Sales | null |
EV / EBITDA | null |
EV / EBIT | null |
EV / FCF | null |
Financial Position
The company has a current ratio of 0.77, with a Debt / Equity ratio of -3.53.
Current Ratio | 0.77 |
Quick Ratio | 0.77 |
Debt / Equity | -3.53 |
Total Debt / Capitalization | 139.45 |
Cash Flow / Debt | -1.44 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 6.18% and return on capital (ROIC) is -229.45%.
Return on Equity (ROE) | 6.18% |
Return on Assets (ROA) | -1.74% |
Return on Capital (ROIC) | -229.45% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.56M |
Employee Count | 14 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.8, so eFFECTOR Therapeutics 's price volatility has been higher than the market average.
Beta | 0.8 |
52-Week Price Change | null% |
50-Day Moving Average | 0.01 |
200-Day Moving Average | 2.09 |
Relative Strength Index (RSI) | 30.34 |
Average Volume (20 Days) | 24.40K |
Income Statement
In the last 12 months, eFFECTOR Therapeutics had revenue of $0 and earned -$35.81M in profits. Earnings per share was $-16.37.
Revenue | 0 |
Gross Profit | -22.92M |
Operating Income | -33.84M |
Net Income | -35.81M |
EBITDA | -33.73M |
EBIT | - |
Earnings Per Share (EPS) | -16.37 |
Balance Sheet
The company has $14.88M in cash and $20.55M in debt, giving a net cash position of -$5.67M.
Cash & Cash Equivalents | 14.88M |
Total Debt | 20.55M |
Net Cash | -5.67M |
Retained Earnings | -179.38M |
Total Assets | 27.13M |
Working Capital | 681.00K |
Cash Flow
In the last 12 months, operating cash flow was -$29.55M and capital expenditures -$97.00K, giving a free cash flow of -$29.65M.
Operating Cash Flow | -29.55M |
Capital Expenditures | -97.00K |
Free Cash Flow | -29.65M |
FCF Per Share | -13.56 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
Gross Margin | 0% |
Operating Margin | 0% |
Pretax Margin | 0% |
Profit Margin | 0% |
EBITDA Margin | n/a% |
EBIT Margin | n/a% |
FCF Margin | n/a% |
Dividends & Yields
EFTR does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | -3150584.48% |
Analyst Forecast
Currently there are no analyst rating for EFTR.
Price Target | $24 |
Price Target Difference | n/a |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Jan 12, 2024. It was a backward split with a ratio of 1:25.
Last Split Date | Jan 12, 2024 |
Split Type | backward |
Split Ratio | 1:25 |
Scores
Altman Z-Score | -13.63 |
Piotroski F-Score | 2 |